% | $
Quotes you view appear here for quick access.

Shire plc Message Board

  • shortningdough shortningdough Nov 6, 2007 11:54 PM Flag

    maybe it's good for adhd

    Shire says study did not meet primary endpoint

    By Angela Moore
    Last Update: 8:20 AM ET Nov 6, 2007Print Subscribe to RSS Disable Live Quotes

    NEW YORK (MarketWatch) - Shire Plc (SHPGY:SHPGY
    News, chart, profile, more

    Delayed quote dataAdd to portfolio
    Create alertInsider
    Sponsored by:
    SHPGY, , ) on Tuesday said a Phase II study of its drug Fosrenol drug did not meet its primary endpoint, to control serum phosphate within normal levels. The company said as a secondary endpoint, patients taking Fosrenol were found to have statistically significant reductions in serum phosphate levels after eight weeks of treatment compared with patients taking a placebo. Shares slipped 1% in premarket trading